You are adding an alert for:
A Multicentre Double-masked Randomised Controlled Non-Inferiority Trial comparing clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion [LEAVO]: Baseline patient sociodemographic and ocular characteristics.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: